CCR6 Antibodies, cDNA Clones Research Reagents

All CCR6 reagents are produced in house and quality controlled, including 2 CCR6 Antibody, 39 CCR6 Gene, 3 CCR6 qPCR. All CCR6 reagents are ready to use.
More Less

All CCR6 Reagents

CCR6 General Information

CCR6 Antibody (2)

Application:
Clonality:
Host:

    CCR6 cDNA Clone (39)

    NM_004367.5

    In cloning vector

    In cloning vector

    In expression vector

    untagged

    C-GFPSpark C-OFPSpark C-DDK tag N-DDK tag C-His tag N-His tag C-HA tag N-HA tag C-Myc N-Myc

    In lentiviral vector

    C-GFPSpark
    NM_001190333.1

    In cloning vector

    In cloning vector

    In expression vector

    untagged

    C-GFPSpark C-OFPSpark C-DDK tag N-DDK tag C-His tag N-His tag C-HA tag N-HA tag C-Myc N-Myc

    In lentiviral vector

    C-GFPSpark
    NM_001013145.1

    In cloning vector

    In cloning vector

    In expression vector

    untagged

    C-GFPSpark C-OFPSpark C-DDK tag N-DDK tag C-His tag N-His tag C-HA tag N-HA tag C-Myc N-Myc

    In lentiviral vector

    C-GFPSpark

    CCR6 qPCR Primer (3)

    More Product Popular With Customers

    CCR6 Background

    Chemokine receptors CCR6 and CCR7 have been reported to play important roles in T cell migration and organ-specific metastasis of various tumors. The expression levels of CCR6 and CCR7 in tumor tissues in patients with lymph node metastases than those without lymph node metastases. CCR6 and CCR7 expressions were also detected in metastatic lymph nodes. CCR6(+) subset of CD4(+) regulatory T cells, a newly characterized subset of Tregs, has been reported to contribute to local immune inhibition. There is a new subset of tumor-resident Tregs, CCR6(+) Tregs, may be dominantly responsible for the immunosuppression in tumor immunity and a potential predictor of the poor prognosis of breast cancer.

    Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.